Specific Detection of Methionine 27 Mutation in Histone 3 Variants (H3K27M) in Fixed Tissue from High-grade Astrocytomas

Overview

Journal Acta Neuropathol

Specialty Neurology

Date 2014 Sep 10

PMID 25200321

Citations 50

Authors

Denise Bechet

Gerrit G H Gielen

Andrey Korshunov

Stefan M Pfister

Caterina Rousso

Damien Faury

Pierre-Olivier Fiset

Naciba Benlimane

Peter W Lewis

Chao Lu

C David Allis

Mark W Kieran

Keith L Ligon

Torsten Pietsch

Benjamin Ellezam

Steffen Albrecht

Nada Jabado

Affiliations

Soon will be listed here.

Abstract

Studies in pediatric high-grade astrocytomas (HGA) by our group and others have uncovered recurrent somatic mutations affecting highly conserved residues in histone 3 (H3) variants. One of these mutations leads to analogous p.Lys27Met (K27M) mutations in both H3.3 and H3.1 variants, is associated with rapid fatal outcome, and occurs specifically in HGA of the midline in children and young adults. This includes diffuse intrinsic pontine gliomas (80 %) and thalamic or spinal HGA (>90 %), which are surgically challenging locations with often limited tumor material available and critical need for specific histopathological markers. Here, we analyzed formalin-fixed paraffin-embedded tissues from 143 pediatric HGA and 297 other primary brain tumors or normal brain. Immunohistochemical staining for H3K27M was compared to tumor genotype, and also compared to H3 tri-methylated lysine 27 (H3K27me3) staining, previously shown to be drastically decreased in samples carrying this mutation. There was a 100 % concordance between genotype and immunohistochemical analysis of H3K27M in tumor samples. Mutant H3K27M was expressed in the majority of tumor cells, indicating limited intra-tumor heterogeneity for this specific mutation within the limits of our dataset. Both H3.1 and H3.3K27M mutants were recognized by this antibody while non-neoplastic elements, such as endothelial and vascular smooth muscle cells or lymphocytes, did not stain. H3K27me3 immunoreactivity was largely mutually exclusive with H3K27M positivity. These results demonstrate that mutant H3K27M can be specifically identified with high specificity and sensitivity using an H3K27M antibody and immunohistochemistry. Use of this antibody in the clinical setting will prove very useful for diagnosis, especially in the context of small biopsies in challenging midline tumors and will help orient care in the context of the extremely poor prognosis associated with this mutation.

Citing Articles

Characterizing the molecular and spatial heterogeneity of midline gliomas in adults: a single institution analysis.

Neth B, Kraft R, Eschbacher K, Johnson D, Decker P, Sener U J Neurooncol. 2025; .

PMID: 40048040 DOI: 10.1007/s11060-025-04994-2.

The "Ins and Outs and What-Abouts" of H2A.Z: A tribute to C. David Allis.

Diegmuller F, Leers J, Hake S J Biol Chem. 2025; 301(2):108154.

PMID: 39761855 PMC: 11808731. DOI: 10.1016/j.jbc.2025.108154.

H3 K27-altered diffuse midline glioma of the thalamus with formation of glio-fibrillary globular structures.

Shintaku M, Hashiba T, Nonaka M, Asai A, Tsuta K Int J Clin Exp Pathol. 2024; 17(7):227-233.

PMID: 39114504 PMC: 11301414. DOI: 10.62347/SRZR7392.

Advances in pediatric gliomas: from molecular characterization to personalized treatments.

Sathyakumar S, Martinez M, Perreault S, Legault G, Bouffet E, Jabado N Eur J Pediatr. 2024; 183(6):2549-2562.

PMID: 38558313 DOI: 10.1007/s00431-024-05540-4.

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.

Arrillaga-Romany I, Lassman A, McGovern S, Mueller S, Nabors B, van den Bent M Neuro Oncol. 2024; 26(Supplement_2):S173-S181.

PMID: 38445964 PMC: 11066938. DOI: 10.1093/neuonc/noae031.

References

Aihara K, Mukasa A, Gotoh K, Saito K, Nagae G, Tsuji S . H3F3A K27M mutations in thalamic gliomas from young adult patients. Neuro Oncol. 2013; 16(1):140-6. PMC: 3870821. DOI: 10.1093/neuonc/not144. View

Wu G, Diaz A, Paugh B, Rankin S, Ju B, Li Y . The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014; 46(5):444-450. PMC: 4056452. DOI: 10.1038/ng.2938. View

Korshunov A, Sturm D, Ryzhova M, Hovestadt V, Gessi M, Jones D . Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathol. 2013; 128(2):279-89. PMC: 4102829. DOI: 10.1007/s00401-013-1228-0. View

Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A . Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009; 118(5):599-601. DOI: 10.1007/s00401-009-0595-z. View

Jones D, Jager N, Kool M, Zichner T, Hutter B, Sultan M . Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012; 488(7409):100-5. PMC: 3662966. DOI: 10.1038/nature11284. View

Wu G, Broniscer A, McEachron T, Lu C, Paugh B, Becksfort J . Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012; 44(3):251-3. PMC: 3288377. DOI: 10.1038/ng.1102. View

Robinson G, Parker M, Kranenburg T, Lu C, Chen X, Ding L . Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012; 488(7409):43-8. PMC: 3412905. DOI: 10.1038/nature11213. View

Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C . Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014; 128(4):573-81. PMC: 4159563. DOI: 10.1007/s00401-014-1319-6. View

Fontebasso A, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset P . Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet. 2014; 46(5):462-6. PMC: 4282994. DOI: 10.1038/ng.2950. View

10.

Pugh T, Weeraratne S, Archer T, Pomeranz Krummel D, Auclair D, Bochicchio J . Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012; 488(7409):106-10. PMC: 3413789. DOI: 10.1038/nature11329. View

11.

Schwartzentruber J, Korshunov A, Liu X, Jones D, Pfaff E, Jacob K . Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482(7384):226-31. DOI: 10.1038/nature10833. View

12.

Venneti S, Garimella M, Sullivan L, Martinez D, Huse J, Heguy A . Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol. 2013; 23(5):558-64. PMC: 3701028. DOI: 10.1111/bpa.12042. View

13.

Dubuc A, Remke M, Korshunov A, Northcott P, Zhan S, Mendez-Lago M . Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol. 2012; 125(3):373-84. PMC: 3580007. DOI: 10.1007/s00401-012-1070-9. View

14.

Taylor K, Mackay A, Truffaux N, Butterfield Y, Morozova O, Philippe C . Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet. 2014; 46(5):457-461. PMC: 4018681. DOI: 10.1038/ng.2925. View

15.

Lewis P, Muller M, Koletsky M, Cordero F, Lin S, Banaszynski L . Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science. 2013; 340(6134):857-61. PMC: 3951439. DOI: 10.1126/science.1232245. View

16.

Zhang J, Wu G, Miller C, Tatevossian R, Dalton J, Tang B . Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet. 2013; 45(6):602-12. PMC: 3727232. DOI: 10.1038/ng.2611. View

17.

Liu X, Gerges N, Korshunov A, Sabha N, Khuong-Quang D, Fontebasso A . Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol. 2012; 124(5):615-25. DOI: 10.1007/s00401-012-1031-3. View

18.

Mack S, Witt H, Piro R, Gu L, Zuyderduyn S, Stutz A . Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014; 506(7489):445-50. PMC: 4174313. DOI: 10.1038/nature13108. View

19.

Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M . Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet. 2014; 46(5):451-6. PMC: 3997489. DOI: 10.1038/ng.2936. View

20.

Sturm D, Witt H, Hovestadt V, Khuong-Quang D, Jones D, Konermann C . Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012; 22(4):425-37. DOI: 10.1016/j.ccr.2012.08.024. View